Gabapentin

Gabapentin Reactions 1704, p168 - 2 Jun 2018 Cognitive impairment and activities of daily living impaired: case report A 64-year-old woman developed cognitive and activities of daily living impairment during treatment with gabapentin for fibromyalgia. The woman presented with a two year history of progressive cognitive decline, which limited her ability to perform instrumental activities of daily living and activities of daily living. She had been receiving gabapentin 300mg TID [route not stated] for two years. Significant attention deficits and executive function by history resulted in the loss of employment as a social worker and driver’s license. Examination revealed montreal cognitive assessment (MoCA) score of 22/30. Two months later, evaluation by a geriatric team showed good recall of recent and distant events. MoCA score was 25/30 with loss of points for sentence repetition, naming and recall. The woman’s therapy with gabapentin was stopped. At two week follow-up, MoCA was 29/30, and her impaired cognition and impaired function resolved. At two month follow-up, her condition sustained. Author comment: "Gabapentin is prescribed for numerous pain syndromes yet has been shown to have little benefit when compared to placebo in the treatment of chronic pain, and is associated with a wide range of adverse effects including cognitive impairment." "This case demonstrates the serious implications of adverse medication effects with gabapentin resulting in significant cognitive and functional impairment." Lantz N, et al. A downward spiral: Dementia or drugs?. Journal of the American Geriatrics Society 66 (Suppl. 2): S264, Apr 2018. Available from: URL: http:// doi.org/10.1111/jgs.15376 [abstract] - USA 803323438 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Gabapentin

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018
Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/gabapentin-reVjGd0J2q
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-018-46811-7
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p168 - 2 Jun 2018 Cognitive impairment and activities of daily living impaired: case report A 64-year-old woman developed cognitive and activities of daily living impairment during treatment with gabapentin for fibromyalgia. The woman presented with a two year history of progressive cognitive decline, which limited her ability to perform instrumental activities of daily living and activities of daily living. She had been receiving gabapentin 300mg TID [route not stated] for two years. Significant attention deficits and executive function by history resulted in the loss of employment as a social worker and driver’s license. Examination revealed montreal cognitive assessment (MoCA) score of 22/30. Two months later, evaluation by a geriatric team showed good recall of recent and distant events. MoCA score was 25/30 with loss of points for sentence repetition, naming and recall. The woman’s therapy with gabapentin was stopped. At two week follow-up, MoCA was 29/30, and her impaired cognition and impaired function resolved. At two month follow-up, her condition sustained. Author comment: "Gabapentin is prescribed for numerous pain syndromes yet has been shown to have little benefit when compared to placebo in the treatment of chronic pain, and is associated with a wide range of adverse effects including cognitive impairment." "This case demonstrates the serious implications of adverse medication effects with gabapentin resulting in significant cognitive and functional impairment." Lantz N, et al. A downward spiral: Dementia or drugs?. Journal of the American Geriatrics Society 66 (Suppl. 2): S264, Apr 2018. Available from: URL: http:// doi.org/10.1111/jgs.15376 [abstract] - USA 803323438 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704

Journal

Reactions WeeklySpringer Journals

Published: Jun 2, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off